Communiqués Mirum Pharmaceuticals, Inc.

Actions

MIRM

US6047491013

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 02/09/2026			Varia. 5j.	Varia. 1 janv.
99,83 ^USD	+1,52%		+1,34%	+26,38%

20/08	Mirum Pharmaceuticals : une dirigeante cède pour 4 000 000 $ d'actions, selon un document de la SEC	MT
19/08	La FDA approuve le traitement de Regeneron contre une maladie osseuse rare	RE

Communiqués

22:05	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences	BU
11/08	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
05/08	Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update	BU
29/07	Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026	BU
14/07	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 13, 2026	AQ
13/07	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
14/06	Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva	BU
11/06	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
04/06	Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026	BU
30/05	Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026	BU
21/05	Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026	BU
14/05	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
13/05	Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes	BU
12/05	Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering	BU
12/05	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences	BU
06/05	Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update	BU
04/05	Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis	BU
03/05	Mirum Pharmaceuticals : to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026	PU
03/05	Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026	BU
29/04	Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026	BU
27/04	Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus	BU
13/04	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
16/03	Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases	BU
12/03	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
05/03	Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus	BU